Novo-Nordisk A/S (NVO) Earnings Date & Reports

Key Takeaways

• Novo Nordisk reports its third-quarter and first nine months of 2026 results on November 4, 2026, before the market open.
• Consensus estimates point to earnings of roughly $0.75 per American Depositary Receipt (ADR) on revenue of about $11.1 billion.
• Both figures would mark year-over-year declines from the $1.02 per ADR and $11.79 billion posted in the same quarter a year earlier.
• Investors are focused on the GLP-1 (glucagon-like peptide-1) obesity and diabetes franchise, including injectable Wegovy, Ozempic, and the newly launched oral Wegovy pill.
• Novo Nordisk has beaten consensus earnings estimates in six of its last eight quarters.

Earnings Context and Why It Matters

Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies on the strength of its GLP-1 treatments for diabetes and obesity. That leadership position is now being tested by intensifying competition, pricing pressure, and shifting demand dynamics in the United States. The third-quarter report will offer investors a timely read on how the company's core franchise is holding up, how the oral Wegovy launch is progressing, and whether rising research and development (R&D) spending is reshaping profitability. With the stock under pressure, the print carries outsized importance for sentiment across the broader weight-loss drug space.

Earnings Expectations

Wall Street expects Novo Nordisk to report adjusted earnings of approximately $0.75 per ADR on revenue near $11.13 billion for the third quarter of 2026. By comparison, the company earned $1.02 per ADR on $11.79 billion in revenue in the prior-year quarter, implying a projected earnings decline of roughly 26% and a revenue decline of about 5.6%.

Those expectations reflect a notable shift from the company's recent momentum. In the second quarter of 2026, Novo Nordisk reported $0.96 per ADR, comfortably beating the $0.77 consensus, on revenue of about $11.98 billion. The company has a strong track record of topping estimates, doing so in six of its last eight quarters, which sets a high bar for this report.

Key figures investors will scrutinize include sales of Ozempic, injectable Wegovy, and the oral Wegovy pill, which management has prioritized as a growth driver. Analysts are also watching U.S. prescription trends, pricing and rebate dynamics, and the impact of generic competition in markets such as Canada and Brazil. Company guidance for the full year, particularly around operating margin and R&D investment, will be a central focus.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking earnings events like Novo Nordisk's upcoming report, it offers a structured way to surface candidates across the healthcare and pharmaceutical sectors. Explore the AI Screener to streamline your research and uncover potential opportunities.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious. Novo Nordisk's shares have been pressured by concerns over GLP-1 competition, moderating prescription growth for Ozempic in the U.S., and lower-priced rivals. Recent analyst commentary has reflected this unease, with some firms trimming price targets on concerns that limited margin expansion and heavy R&D spending will constrain profit growth over the medium term.

The stock has historically shown a meaningful reaction around earnings, and investors will be watching whether management's commentary on the oral Wegovy launch and 2026 guidance can reassure the market. The oral Wegovy pill is seen as a potential bright spot, with early international launches drawing attention. A notable beat on pill sales, or an upgrade to full-year guidance, could ease investor concerns, while softer injectable trends or weaker margin signals could reinforce the cautious tone.

Forward Outlook and Key Factors to Monitor

Following the report, investors should track several themes that will shape Novo Nordisk's trajectory. The oral Wegovy rollout is a top priority. Management has signaled plans to expand the pill's availability across multiple markets, leveraging improved manufacturing capacity, and the pace of that expansion will be a key demand signal for the obesity franchise.

Pricing and competition remain central risks. Continued declines in U.S. Ozempic prescriptions, generic launches in international markets, and pressure on injectable Wegovy pricing could weigh on revenue growth even as volume expands. How the company balances these headwinds against new product momentum will be closely watched.

Margin and R&D investment are equally important. Novo Nordisk has guided toward broadly stable margins through the end of the decade while ramping up R&D spending, a combination that limits near-term earnings growth. Investors will look for signs of whether cost discipline can offset those investments over time.

Finally, full-year guidance and any updates on the competitive landscape, including rival GLP-1 offerings and oral treatments, will help frame expectations for the quarters ahead. These factors, rather than any single data point, are likely to determine the stock's direction after the report.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations